- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06798896
Renaissance 2: SPN-817 Fase 2, dobbeltblind, placebokontrollert studie hos voksne med fokalbeslagede anfall
Renaissance 2: En dobbeltblind, randomisert, placebokontrollert, multisenter, parallellgruppeundersøkelse for å evaluere effektiviteten, sikkerheten og toleransen av SPN-817 hos voksne med fokal utbrudd av anfall
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 administered as an adjunctive treatment in adults with focal onset seizures that have previously failed at least 2 anti-seizure medication (ASM) regimens. Participants will be taking 1 to 4 ASMs, with at least 4 seizures during the 6-week Screening Period. Following the Screening Period, eligible participants will be randomized 2:1 to SPN-817 (3.0-4.0 mg BID) or placebo and begin the Titration Period (8-10 weeks). In both treatment groups, open-label ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic adverse events [AEs]) will be taken (8 mg oral [PO]) prophylactically approximately 30 minutes before each study medication (SM) dose (ie, BID) during the Titration Period as an antiemetic. After the target dose of 3.0-4.0 mg BID is reached, participants will enter the Maintenance Period (14 weeks). Ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic AEs) may be taken as needed as either a preventative or therapeutic antiemetic during the Maintenance Period. Participants who complete the Maintenance Period will have the opportunity to enroll in a separate open-label study for continued treatment with SPN-817. Participants who do not enroll in the open-label study will undergo a Tapering Period (up to 4 weeks) and a follow-up safety phone call.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Navid Saeidi, MS
- Telefonnummer: 240-403-5328
- E-post: nsaeidi@supernus.com
Studer Kontakt Backup
- Navn: Supernus Clinical Trials
- Telefonnummer: 240-403-5838
- E-post: clinicaltrials@supernus.com
Studiesteder
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- Rekruttering
- Royal Brisbane and Women's Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Rekruttering
- Royal Adelaide Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Rekruttering
- Monash Medical Centre
-
Fitzroy, Victoria, Australia, 3065
- Rekruttering
- St. Vincent's Hospital Melbourne
-
Melbourne, Victoria, Australia, 3004
- Rekruttering
- The Alfred Hospital
-
Parkville, Victoria, Australia, 3052
- Rekruttering
- Royal Melbourne Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Rekruttering
- The Perron Institute for Neurological and Translational Science
-
-
-
-
-
Blagoevgrad, Bulgaria, 2700
- Rekruttering
- Multiprofile Hospital for Active Treatment PULS
-
Pleven, Bulgaria, 5809
- Rekruttering
- Medical Center (MC) Academica
-
Rousse, Bulgaria, 7012
- Rekruttering
- Medical Center - Teodora EOOD
-
Sofia, Bulgaria, 1113
- Rekruttering
- Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "Sveti Naum" EAD
-
-
Sofia-Grad
-
Sofia, Sofia-Grad, Bulgaria, 1431
- Rekruttering
- University Multiprofile Hospital for Active Treatment Aleksandrovska, Clinic for Neurology Diseases
-
-
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85004
- Rekruttering
- Xenoscience
-
Phoenix, Arizona, Forente stater, 85006
- Rekruttering
- Banner University Medical Center-Phoenix
-
Tucson, Arizona, Forente stater, 85724
- Rekruttering
- University of Arizona College of Medicine - Tucson
-
Tucson, Arizona, Forente stater, 85718
- Rekruttering
- Center for Neurosciences
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- Rekruttering
- Clinical Trials, Inc
-
-
California
-
Los Angeles, California, Forente stater, 90048
- Rekruttering
- Clinical Research Institute
-
Mission Hills, California, Forente stater, 91345
- Rekruttering
- Access Community Clinical Trials
-
Orange, California, Forente stater, 92868
- Rekruttering
- University of California, Irvine
-
West Hills, California, Forente stater, 91307
- Rekruttering
- Focus Clinical Research
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Rekruttering
- Yale University
-
-
Florida
-
Gulf Breeze, Florida, Forente stater, 32561
- Rekruttering
- Northwest Florida Clinical Research Group, LLC
-
Kissimmee, Florida, Forente stater, 34744
- Rekruttering
- Ilumina Medical Research
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami
-
Miami, Florida, Forente stater, 33133
- Rekruttering
- Visionary Investigators Network
-
Orlando, Florida, Forente stater, 32806
- Avsluttet
- Research Institute of Orlando, LLC
-
Port Charlotte, Florida, Forente stater, 33952
- Rekruttering
- Medsol Clinical Research Center
-
Ta kontakt med:
- Maria Vasconcelos, RN
- Telefonnummer: 941-623-9744
- E-post: mvasconcelos@medsolcrc.com
-
Port Saint Lucie, Florida, Forente stater, 34990
- Rekruttering
- Cleveland Clinic Florida Martin Health
-
-
Illinois
-
Springfield, Illinois, Forente stater, 62702
- Rekruttering
- Southern Illinois University School of Medicine
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40223
- Rekruttering
- University of Louisville Physicians
-
-
Louisiana
-
Covington, Louisiana, Forente stater, 70433
- Rekruttering
- Neurocare of Louisiana
-
New Orleans, Louisiana, Forente stater, 70121
- Suspendert
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Rekruttering
- Johns Hopkins University
-
Bethesda, Maryland, Forente stater, 20817
- Rekruttering
- Mid Atlantic Epilepsy and Sleep Center
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48201
- Rekruttering
- Wayne State University - Detroit Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Rekruttering
- Northeast Regional Epilepsy Group - Hackensack
-
Neptune City, New Jersey, Forente stater, 07753
- Rekruttering
- Hackensack Meridian Health Jersey Shore University Medical Center
-
-
New York
-
Albany, New York, Forente stater, 12208
- Rekruttering
- Albany Medical Center
-
Amherst, New York, Forente stater, 14226
- Rekruttering
- Dent Neurologic Institute
-
New York, New York, Forente stater, 10021
- Rekruttering
- Northwell Health - Lenox Hill
-
Rochester, New York, Forente stater, 14618
- Rekruttering
- University of Rochester Medical Center
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28806
- Rekruttering
- Asheville Neurology Specialists
-
Charlotte, North Carolina, Forente stater, 28211
- Rekruttering
- OnSite Clinical Solutions, LLC
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Neurology Institute Epilepsy Center of Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Rekruttering
- Thomas Jefferson University
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Vanderbilt University Medical Center
-
-
Texas
-
El Paso, Texas, Forente stater, 79912
- Rekruttering
- Advanced Neurology Epilepsy and Sleep Center/ANESC Research
-
Frisco, Texas, Forente stater, 75034
- Rekruttering
- Stryde Research
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- UT Health Houston
-
-
Virginia
-
McLean, Virginia, Forente stater, 22101
- Rekruttering
- Medstar Health Research Institute
-
-
-
-
-
Lublin, Polen, 20-064
- Rekruttering
- NZOZ NEUROMED M. and M. Nastaj Spółka Partnerska
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-727
- Rekruttering
- Pratia MCM Kraków
-
-
Maloplski
-
Krakow, Maloplski, Polen, 30-363
- Rekruttering
- Centrum Medyczne Plejady
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 01-684
- Rekruttering
- Centrum Medyczne NeuroProtect
-
Warsaw, Masovian Voivodeship, Polen, 02-172
- Rekruttering
- TZ Clinical Research powered by Pratia
-
Warsaw, Masovian Voivodeship, Polen, 02-952
- Rekruttering
- Neurosphera
-
-
Pomeranian Voivodeship
-
Gdynia, Pomeranian Voivodeship, Polen, 81-537
- Rekruttering
- Synexus Polska Sp. z o. o. Oddział w Gdyni
-
Sopot, Pomeranian Voivodeship, Polen, 81-735
- Suspendert
- Terra Centrum Leczenia
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polen, 40-123
- Rekruttering
- NZOZ Wielospacjalistyczna Poradnia Lekarska Synapsis
-
Katowice, Silesian Voivodeship, Polen, 40-650
- Rekruttering
- Novo-Med Zieliński i Wsp. Sp.J.
-
-
-
-
-
Budapest, Ungarn, 1125
- Rekruttering
- Flash Clinic
-
Budapest, Ungarn, 1145
- Rekruttering
- SE, Idegsebeszeti es Neurointervencios Klinika, Epilepszia Centrum
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of treatment-resistant focal epilepsy as adjudicated by the Epilepsy Study Consortium, Inc (ESCI);
- Failed to achieve sustained seizure freedom after ≥2 tolerated, appropriately chosen, and adequately dosed ASM drug schedules;
- Able to keep accurate Seizure electronic diaries [eDiaries] (with the aid of a caregiver as needed);
- Has a body mass index (BMI) between 18.0 and 40.0 kg/m2;
- Treatment with a stable dose of 1 to 4 current ASMs for ≥28 days prior to screening. If following a diet plan along with the ASM, the participant should have been on a stable diet plan for at least 1 month prior to Visit 1. The diet plan should be maintained throughout the duration of the study;
- At least 4 clinically observable focal onset seizures accepted by the ESCI prior to the first dose of SM (during the days of baseline Seizure electronic diary [eDiary] data collection) and no more than a consecutive 21-day period that was free of these seizures. To be eligible for the study, participants must comply with the eDiary on at least 80% of the days of baseline data collection;
Exclusion Criteria:
- Has taken huperzine A within the past 6 months;
- Prior diagnosis of combined focal and generalized epilepsy syndrome as evidenced by severe developmental delay and multiple seizure types and confirmed by electroencephalography (EEG) (eg, Lennox-Gastaut syndrome). Participants should also be excluded in case of nondiagnostic information;
- History of or current nonepileptic events that could be confused by the participant and/or study staff as epileptic seizures;
- Only has seizures that are difficult to count; for example, seizures that are not clinically observable;
- History of uncountable seizures, such as seizures that happen in a cluster that are too rapid to be counted individually;
- History of status epilepticus within 6 months prior to screening;
- Vagus nerve stimulation, deep brain stimulation, responsive neurostimulator system, or other neurostimulation for epilepsy device implanted or activated within 1 year prior to screening; or epilepsy surgery within 1 year prior to screening. Stimulation parameters for devices must have been stable for at least 3 months prior to Screening. Battery change for any epilepsy devices will be allowed; however, stimulation parameters must remain stable during the duration of the study;
- Any suicidal behavior or suicidal ideation related to item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS assessment in the 1 year before screening; a suicide attempt in the last 2 years before screening; or more than 1 lifetime suicide attempt;
- Chronic concomitant therapy with non-ASMs that have potent cholinergic (central or peripheral) or potent central (only) anticholinergic pharmacology.
- History of >2 allergic reactions to an ASM or 1 serious hypersensitivity reaction to an ASM;
- Any other reason which, in the opinion of the Investigator, would prevent the participant from taking part in the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: SPN-817
SPN-817, bid |
SPN-817 starting at 0.25 mg bid up to 4.00 mg bid |
|
Placebo komparator: Placebo
Placebo, bid |
Placebo, bid |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period
Tidsramme: Baseline and Maintenance Period (Maintenance Week 1-14)
|
Percent change in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline |
Baseline and Maintenance Period (Maintenance Week 1-14)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Tidsramme: Baseline and Maintenance Period (Maintenance Week 1-14)
|
Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline. |
Baseline and Maintenance Period (Maintenance Week 1-14)
|
|
PCH from baseline in focal onset seizure frequency per 28 days over the entire Treatment Period
Tidsramme: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
Percent change in 28-day frequency of focal seizures during the entire Treatment Period (Titration Period + Maintenance Period) relative to baseline |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Tidsramme: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the Treatment Period (Titration Period + Maintenance Period) relative to baseline. |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Longest seizure-free interval over the entire Treatment Period
Tidsramme: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
The longest intervals in days between two seizures during the entire Treatment Period. |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Incidence of treatment-emergent adverse events (TEAEs)
Tidsramme: Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4
|
The percent of subjects who took at least one dose of SPN-817 and reported at least one adverse event during SPN-817 treatment. |
Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Maciej Gasior, MD, PhD, Supernus Pharmaceuticals, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 817P203
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .